In this study, we demonstrated that SDC-4 expression levels in PBMCs obtained prior to WT1 vaccination were significantly and negatively correlated with OS of recurrent or conventional therapy-resistant GBM patients who were treated with WT1 peptide vaccine, and that SDC-4 expression levels were a useful biomarker for prediction of clinical outcome. This evidence concerns the gene WT1 and glioblastoma.